| http://www.w3.org/ns/prov#value | - (LVAD) in a 2:1 ratio.Patients receiving the HeartWare ventricular assist system or control LVAD will be followed to the primary endpoint at two years, with a subsequent follow-up period extending to five years post implant.The study's primary endpoint is survival at two years, while the secondary endpoints include adverse events such as bleeding and infection, as well as functional status, hospi
|
